Intraarterial carboplatin combined with radiotherapy for relapsing glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of intraarterial (IA) carboplatin in combination with radiotherapy for patients with relapsing glioblastoma multiforme (GBM). The study aims to improve treatment outcomes by bypassing the blood-brain barrier, which limits the effectiveness of traditional chemotherapy. Patients will undergo surgery for tumor reduction and sample collection, followed by concurrent IA carboplatin and radiation therapy. The trial is designed to assess the safety and efficacy of this novel approach in enhancing progression-free survival and overall survival in this challenging patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histological diagnosis of glioblastoma multiforme
2. Radiological progression on an MRI scan, according to the RANO criteria, in the context of a known glioblastoma multiforme, already treated with the Stupp protocol of combined radiotherapy-Temozolomide, and progressing. This implies a measurable disease on MRI.
3. Prior radiotherapy and temozolomide, as per the Stupp protocol, no sooner than 4 weeks, is permitted.
4. 18 of age and over
5. Performance status: Karnofsky 60-100%
6. Haematopoietic parameters at enrolment:

   * Platelet counts \> 100,000/mm\^3
   * Hemoglobin \> 8 g/dL
   * Absolute neutrophil count \> 1,500/mm\^3
   * No impaired bone marrow function
7. Hepatic parameters at enrolment:

   * Bilirubin ≤ 2 times normal value
   * AST and ALT ≤ 2 times upper limit of normal (ULN) Alkaline phosphatase ≤ 2 times ULN (unless attributed to tumor)
   * No impaired hepatic function
8. Renal parameters at enrollment:

   * No impaired renal function
   * Creatinine no greater than 1.5 fold of the normal value
   * Creatinine clearance \> 30 ml/min.
9. Normal ECG
10. Written informed consent obtained
11. Patient should be either sterile or else use a contraceptive strategy (for at least 2 months prior to study accrual).

    \-

Exclusion Criteria:

1. Presence of a severe psychiatric or medical condition that would interfere with treatment administration or study enrolment.
2. Presence of an active auto-immune disease.
3. Occurrence of another malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
4. Pregnancy (as objectivated by a positive b-HCG) or actively nursing
5. Presence of an uncontrolled systemic infection

Where it's running

• Chus
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: David Fortin, MD — Crc-Chus
• Study coordinator: David Fortin, MD
• Email: david.fortin@usherbrooke.ca
• Phone: 819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two chemotherapy combinations for treating relapsed glioblastoma

  This study is testing two different chemotherapy combinations to see if they can help people with relapsed glioblastoma live longer and feel better.

  Recruiting Phase 2 Université de Sherbrooke · Sherbrooke, Quebec · NCT06356883

• How facial type relates to relapse after orthodontic treatment during retention

  This study tests whether people with different facial types have different patterns of tooth movement relapse after orthodontic treatment during the retention phase.

  Recruiting Postgraduate Institute of Dental Sciences Rohtak · Rohtak, Haryana · NCT07622277

• Can a multi-omics and AI model predict ABPA relapse within 1 year in adults?

  This study tests a machine learning model that uses multi-omics and clinical data to predict the 1-year relapse risk for adults with ABPA who are in a stable state.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07611838

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

• How iNKT immune cells after allogeneic stem cell transplant relate to transplant complications

  This study tests whether levels of invariant NKT cells in the blood after an allogeneic stem cell transplant can be linked to complications like GvHD, infections, or relapse in patients with AML.

  Recruiting University Hospital Pilsen · Pilsen, Czechia · NCT07570407

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.